Get to know our clinical trials
Clinical trial of orally administered RVU120 for the treatment of anemia in patients with low-risk myelodysplastic neoplasm (MDS).
THE PURPOSE OF THIS STUDY IS TO OBTAIN INFORMATION ON THE EFFICACY AND SAFETY OF RVU120 IN THE TREATMENT OF MDS DUE TO ANEMIA (LOW RED BLOOD CELL COUNT). THE STUDY IS BEING CONDUCTED TO DETERMINE IF TREATMENT WITH THE NEW DRUG RVU120 IS SAFE AND REDUCES THE NEED AND/OR FREQUENCY OF RED BLOOD CELL TRANSFUSIONS IN PATIENTS WITH MDS. WE CONDUCTED THIS STUDY TO UNDERSTAND WHETHER THE NEW APPROACH IS AN IMPROVEMENT FOR PATIENTS WITH RESPECT TO THE TREATMENT OF THEIR ANEMIA.
Technical Summary
- A MULTICENTER OPEN-LABEL PHASE II TRIAL OF ORALLY ADMINISTERED RVU120 FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH LOW-RISK MYELODYSPLASTIC NEOPLASM (MDS).
- Code EudraCT: 2023-509947-29
- Protocol number: REMARK_001
- Promoter: Red de Apoyo a la Investigación Clínica en Hematología y Hemoterapia(RAICH
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.